Avian influenza vaccines against H5N1 'bird flu'

Trends in Biotechnology

Volumn 32, Issue 3, 2014, Pages 147-156

  Li, Chengjun ^a   Bu, Zhigao ^a   Chen, Hualan ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Avian influenza; H5N1; Vaccine

Indexed keywords

AVIAN INFLUENZA; H5N1; VACCINE;

BIOTECHNOLOGY; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MASS VACCINATION;

EID: 84894257418     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.01.001     Document Type: Review

References (79)

1. Tong S., et al. New world bats harbor diverse influenza a viruses. PLoS Pathog. 2013, 9:e1003657.
2. Tong S., et al. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:4269-4274.
3. Swayne D.E. Impact of vaccines and vaccination on global control of avian influenza. Avian Dis. 2012, 56:818-828.
4. Swayne D.E., et al. Assessment of national strategies for control of high-pathogenicity avian influenza and low-pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination. Rev. Sci. Tech. 2011, 30:839-870.
5. Spackman E., Swayne D.E. Vaccination of gallinaceous poultry for H5N1 highly pathogenic avian influenza: current questions and new technology. Virus Res. 2013, 178:121-132.
6. Imai M., et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486:420-428.
7. Herfst S., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336:1534-1541.
8. Zhang Y., et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 2013, 340:1459-1463.
9. Tang D.C., et al. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev. Vaccines 2009, 8:469-481.
10. Swayne D.E. Avian influenza vaccines and therapies for poultry. Comp. Immunol. Microbiol. Infect. Dis. 2009, 32:351-363.
11. Horimoto T., Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol. Med. 2006, 12:506-514.
12. Luke C.J., Subbarao K. Vaccines for pandemic influenza. Emerg. Infect. Dis. 2006, 12:66-72.
13. Wood J.M., Robertson J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2004, 2:842-847.
14. Subbarao K., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305:192-200.
15. Senne D.A., et al. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis. 1996, 40:425-437.
16. Chen H., et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10452-10457.
17. Xu X., et al. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999, 261:15-19.
18. Tian G., et al. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology 2005, 341:153-162.
19. Rudolf M., et al. Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens. Vaccine 2010, 28:6832-6840.
20. Terregino C., et al. Evaluation of the protection induced by avian influenza vaccines containing a 1994 Mexican H5N2 LPAI seed strain against a 2008 Egyptian H5N1 HPAI virus belonging to clade 2.2.1 by means of serological and in vivo tests. Avian Pathol. 2010, 39:215-222.
21. Poetri O.N., et al. An inactivated H5N2 vaccine reduces transmission of highly pathogenic H5N1 avian influenza virus among native chickens. Vaccine 2009, 27:2864-2869.
22. Bublot M., et al. Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand. Avian Dis. 2007, 51:332-337.
23. Beato M.S., et al. A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1. Vaccine 2007, 25:4064-4072.
24. Swayne D.E., et al. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathol. 2006, 35:141-146.
25. Liu M., et al. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. Virology 2003, 314:580-590.
26. Hwang S.D., et al. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus. Vaccine 2011, 29:2178-2186.
27. Kim J.K., et al. Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. J. Virol. 2008, 82:11374-11382.
28. Webster R.G., et al. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 2006, 351:303-311.
29. Middleton D., et al. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks. Virology 2007, 359:66-71.
30. Tian G., et al. Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam. Avian Dis. 2010, 54:287-289.
31. Paoletti E. Poxvirus recombinant vaccines. Ann. N. Y. Acad. Sci. 1990, 590:309-325.
32. Webster R.G., et al. Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant. Avian Dis. 1996, 40:461-465.
33. Taylor J., et al. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 1988, 6:504-508.
34. Qiao C.L., et al. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol. 2003, 32:25-32.
35. Qiao C., et al. Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus. Antiviral Res. 2009, 81:234-238.
36. Qiao C., et al. Vaccines developed for H5 highly pathogenic avian influenza in China. Ann. N. Y. Acad. Sci. 2006, 1081:182-192.
37. Qian C., et al. The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks. Vaccine 2012, 30:6279-6286.
38. Swayne D.E., et al. Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine 2000, 18:1088-1095.
39. Bublot M., et al. Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge. Avian Dis. 2007, 51:498-500.
40. Swayne D.E., et al. Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis. 2000, 44:132-137.
41. Chen H., Bu Z. Development and application of avian influenza vaccines in China. Curr. Top. Microbiol. Immunol. 2009, 333:153-162.
42. Swayne D.E., et al. Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease. Avian Dis. 2003, 47:1047-1050.
43. Nayak B., et al. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS ONE 2009, 4:e6509.
44. Ge J., et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 2007, 81:150-158.
45. Veits J., et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8197-8202.
46. Romer-Oberdorfer A., et al. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus. Vaccine 2008, 26:2307-2313.
47. Ferreira H.L., et al. Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis. 2012, 56:940-948.
48. Niqueux E., et al. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus. Vaccine 2013, 31:4121-4128.
49. Tsukamoto K., et al. Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J. Virol. 2002, 76:5637-5645.
50. Sondermeijer P.J., et al. Avian herpesvirus as a live viral vector for the expression of heterologous antigens. Vaccine 1993, 11:349-358.
51. Rauw F., et al. Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old. Vaccine 2010, 28:823-833.
52. Li Y., et al. Recombinant herpesvirus of turkeys as a vector-based vaccine against highly pathogenic H7N1 avian influenza and Marek's disease. Vaccine 2011, 29:8257-8266.
53. Gao H., et al. Expression of HA of HPAI H5N1 virus at US2 gene insertion site of turkey herpesvirus induced better protection than that at US10 gene insertion site. PLoS ONE 2011, 6:e22549.
54. Rauw F., et al. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains. Vaccine 2011, 29:2590-2600.
55. Rauw F., et al. Efficacy of rHVT-AI vector vaccine in broilers with passive immunity against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains. Avian Dis. 2012, 56:913-922.
56. Deng G., et al. Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the dongting lake region of china. J. Virol. 2013, 87:9452-9462.
57. Liu J., et al. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J. Virol. 2011, 85:10989-10998.
58. Liu J., et al. Recombinant duck enteritis virus works as a single-dose vaccine in broilers providing rapid protection against H5N1 influenza infection. Antiviral Res. 2013, 97:329-333.
59. Veits J., et al. Deletion of the non-essential UL0 gene of infectious laryngotracheitis (ILT) virus leads to attenuation in chickens, and UL0 mutants expressing influenza virus haemagglutinin (H7) protect against ILT and fowl plague. J. Gen. Virol. 2003, 84:3343-3352.
60. Pavlova S.P., et al. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype. Vaccine 2009, 27:5085-5090.
61. Pavlova S.P., et al. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. Vaccine 2009, 27:773-785.
62. Luschow D., et al. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene. Vaccine 2001, 19:4249-4259.
63. Fuchs W., et al. Novel avian influenza virus vaccines. Rev. Sci. Tech. 2009, 28:319-332.
64. Kim J.H., Jacob J. DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol. 2009, 333:197-210.
65. Kodihalli S., et al. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000, 18:2592-2599.
66. Suarez D.L., Schultz-Cherry S. The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in chickens using an avian influenza model. Avian Dis. 2000, 44:861-868.
67. Fynan E.F., et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:11478-11482.
68. Jiang Y., et al. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antiviral Res. 2007, 75:234-241.
69. Rao S., et al. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS ONE 2008, 3:e2432.
70. Zhou F., et al. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J. Virol. 2012, 86:6970-6978.
71. Liniger M., et al. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS ONE 2012, 7:e49952.
72. Yao Q., et al. Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. Vaccine 2010, 28:8147-8156.
73. Li J., et al. Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail. Avian Dis. 2012, 56:937-939.
74. Ellis T.M., et al. Vaccination of chickens against H5N1 avian influenza in the face of an outbreak interrupts virus transmission. Avian Pathol. 2004, 33:405-412.
75. Chen H. Avian influenza vaccination: the experience in China. Rev. Sci. Tech. 2009, 28:267-274.
76. Barnett P., et al. Aspects of emergency vaccination against foot-and-mouth disease. Comp. Immunol. Microbiol. Infect. Dis. 2002, 25:345-364.
77. Heymann D.L., Aylward R.B. Mass vaccination: when and why. Curr. Top. Microbiol. Immunol. 2006, 304:1-16.
78. van Oirschot J.T. Diva vaccines that reduce virus transmission. J. Biotechnol. 1999, 73:195-205.
79. Henderson L.M. Overview of marker vaccine and differential diagnostic test technology. Biologicals 2005, 33:203-209.